Table 4.
Univariate and multivariate logistic regression analysis of risk factors for the occurrence of severe irAEs.
| Univariate | Multivariate | |||||
|---|---|---|---|---|---|---|
| OR | 95%CI | P value | OR | 95%CI | P value | |
| Age: ≥65 years | 0.87 | 0.44-1.71 | 0.68 | 0.97 | 0.34-2.79 | 0.96 |
| Gender: male | 0.83 | 0.37-1.89 | 0.67 | 1.35 | 0.36-4.92 | 0.65 |
| IMDC risk group: Poor | 0.69 | 0.36-1.34 | 0.27 | 1.93 | 0.48-7.68 | 0.35 |
| Karnofsky Performance Status: ≥80 | 1.95 | 0.87-4.35 | 0.10 | 2.21 | 0.57-8.54 | 0.25 |
| Histological subtype, Clear cell: Yes | 1.05 | 0.53-2.09 | 0.88 | 1.37 | 0.45-4.12 | 0.57 |
| NLR in baseline sample: ≥3.0 | 1.06 | 0.55-2.04 | 0.85 | 1.10 | 0.35-3.39 | 0.87 |
| NLR in 3-week sample: ≥3.0 | 0.82 | 0.40-1.66 | 0.58 | |||
| PLR in baseline sample: ≥150 | 0.95 | 0.45-2.00 | 0.89 | 1.07 | 0.32-3.52 | 0.90 |
| PLR in 3-week sample: ≥150 | 0.50 | 0.24-1.04 | 0.06 | |||
| Proportion of eosinophils: ≥3.0% | 4.19 | 1.53-11.5 | <0.05 | 6.01 | 1.81-20.0 | <0.05 |
CI, confidence interval; IMDC, International Metastatic Renal Cell Carcinoma Database Consortium; irAE, immune-related adverse event; OR, odds ratio; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio.